Theravance Inc. (THRX): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Theravance ( THRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.4%. By the end of trading, Theravance rose $0.39 (1.1%) to $37.20 on light volume. Throughout the day, 312,791 shares of Theravance exchanged hands as compared to its average daily volume of 1,424,300 shares. The stock ranged in a price between $36.62-$37.62 after having opened the day at $36.68 as compared to the previous trading day's close of $36.81. Other companies within the Drugs industry that increased today were: NPS Pharmaceuticals ( NPSP), up 25.4%, Geron Corporation ( GERN), up 16.4%, Aastrom Biosciences ( ASTM), up 16.3% and GW Pharmaceuticals PLC ADR ( GWPH), up 16.0%.

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Theravance has a market cap of $4.0 billion and is part of the health care sector. Shares are up 65.5% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Theravance as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and disappointing return on equity.

On the negative front, Mast Therapeutics ( MSTX), down 41.8%, Tonix Pharmaceuticals ( TNXP), down 30.2%, Dendreon ( DNDN), down 26.1% and Genvec ( GNVC), down 23.2% , were all laggards within the drugs industry with Johnson & Johnson ( JNJ) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Flagged As Strong On High Volume

Theravance (THRX) Flagged As Strong On High Volume

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

The 10 Highest Dividend Health Care Stocks Are Not All Buys

The 10 Highest Dividend Health Care Stocks Are Not All Buys

5 Hated Stocks You Should Love This Earnings Season

5 Hated Stocks You Should Love This Earnings Season